Clinical Trials at Institute of Medical Science and SUM Hospital

| SINO | Principal | Department | Title of study proposal | Year | Status | National / |
|------|----------------------------|-------------------|--|------|--------|---------------|
| | Investigator Name | | | | | International |
| 1. | Dr. Chandan Das | Internal Medicine | A multicentric, open label, randomized, comparative, parallel group, active control phse iii clinical trial to evaluate safety and efficacy of arbekacin sulfate injection versus vancomycin injection in patients dignosed with mrsa infection | 2016 | Closed | National |
| 2. | Dr. Jyoti Ranjan Parida | Immunology | International comparative multicenter double blind randomized clinical study of efficacy and safety of bcd-055 (CJSC Biocad, Russia) and remicade in combination with methotrexate in patients with active rheumatoid arthritis. | 2016 | Closed | International |
| 3. | Dr. Soumya Surath Panda | Medical Oncology | A Prospective, Multicenter, Randomized, Double-blind, Parallel group Study to Compare the Efficacy and Safety of GBR 200 (similar biologic of Trastuzumab) versus Innovator Trastuzumab both when given in combination with Paclitaxel in | 2017 | Closed | National |

(Siksha 'O' Anusandhan Deemed to be University)

| | | | Patients Diagnosed with HER2 Positive Metastatic Breast Cancer. | | | |
|----|---------------------|------------|---|------|--------|---------------|
| 4. | Dr.Manisha Sahu | Gynecology | A Prospective, Multicentric, Phase IV Clinical Study evaluating safety and efficacy of Leuprorelin 3.5mg injection plus Enzomac Tablet (Trypsin 96 mg + Bromelain 180 mg +Rutoside Trihydrate 200 mg) versus Leuprorelin 3.5mg injection in the treatment of patients diagnosis with Endometriosis | 2017 | Closed | National |
| 5. | Dr.Manisha Sahu | Gynecology | An Open label, Prospective, Comparative, Randomized, Phase IV Clinical Study evaluating safety and efficacy of Menojoy capsule Versus Soya isoflavones capsule Versus Primarine 0.3 mg Tablets in patients with postmenopausal | 2017 | Closed | National |
| 6. | Dr. Jagannath Sahoo | Orthopedic | A Randomized, Double blind, Three-arm, Parallel, Placebo- controlled, Clinical Study to Evaluate the Bioequivalence using Clinical Endpoint of Diclofenac Sodium Gel, 1% (Mylan Inc.) to Voltaren® Gel (Diclofenac Sodium Topical Gel) 1% (Novartis Consumer Health, Inc.) in Patients with Osteoarthritis (OA) of the Knee | 2017 | Closed | International |

| 7. | Dr. Sourav Kumar Mishra/Dr Soumya surath Panda | Medical Oncology | A Phase-I/II, Open Label, Dose- Finding Study of DO-013 Alone and In Combination with Gemcitabine among Patients with Advanced Carcinoma of Pancreas. | 2017 | Closed | National |
|-----|--|------------------|--|------|---------|---------------|
| 8. | Dr. Abhay Kumar Sahoo | Endocrinology | A randomised, multi-centric, double blinded, comparative study to evaluate efficacy and safety of fixed dose combination of Pregabalin and Amitriptyline in comparison to monotherapy of Pregabalin and Amitriptyline in patients having Neuropathic Pain in India | 2017 | Ongoing | National |
| 9. | Dr. Bikash ranjan Kar | Skin & VD | A multi-centric open label, single arm study to evaluate efficacy and safety of High Dose of Desloratidine (10 mg) in the treatment of Chronic Idiopathic Urticaria in India | 2017 | Closed | National |
| 10. | Dr. Bikash ranjan Kar | Skin & VD | A Multicenter Comparative Randomized Double-blind Study of the Efficacy and Safety of BCD-057 (INN: Adalimumab, CJSC BIOCAD, Russia) and Humira® (INN: Adalimumab, Vetter Pharma) in Patients with Moderate to Severe Plaque Psoriasis | 2018 | Closed | International |
| 11. | Dr. Ayaskanta Singh | Gastroenterology | A randomized, multi-centric, active controlled, parallel, open- label, comparative study to | 2018 | Closed | National |

| 12. | Dr. Sourav Kumar Mishra/ Dr Priyanka Samal | Medical Oncology/Haematology | evaluate efficacy and safety of pantoprazole dual-release Gastro- resistant tablet in comparison to Pantoprazole tablet in patients having refractory moderate to severe GERD (Gastro Esophageal Reflux Disease) in India A phase 3 randomized, controlled, open-label study of selinexor, bortezomib, and dexamethasone (SVD) versus bortezomib and dexamethasone (Vd) in patients with relapsed or refractory | 2018 | Closed | International |
|-----|--|---------------------------------|---|------|---------|---------------|
| 13. | Dr. Sourav Kumar Mishra/ Dr Priyanka Samal | Medical Oncology/Haematology | multiple myeloma (RRMM) A phase 2b open-label study of selinexor (KPT-330) in patients with relapsed/refractory diffuse large B-cell lymphoma (DLBCL) | 2018 | Closed | International |
| 14. | Dr. Debadarshi Rath | Urology | A randomized, multi-centric, double blind, comparative study to evaluate efficacy and safety of fixed dose combination of Alfuzosin hydrochloride extended release and Tadalafil in comparison to Alfuzosin hydrochloride extended release in patients having Benign Prostatic Hyperplasia (BPH) and Lower urinary tract symptoms (LUTS) in India | 2018 | Ongoing | National |
| 15. | Dr. Sourav Kumar Mishra /Priya P Nayak | Medical Oncology | A single arm, multicentric, open label, efficacy and safety study of | | Ongoing | National |

| | | . (| Docetaxel Lipid Suspension for Injection of Intas Pharmaceuticals Limited, India in patients with Metastatic Castration Resistant | 2018 | | |
|-----|--------------------------|---------------|---|------|---------|----------|
| 16. | Dr. Debadarshi Rath | Urology | prostate cancerA Phase-III, Multicentric, Randomized, Double Blind, Placebo-Controlled, Comparative Clinical Study to Evaluate the Efficacy and Safety of Tadalafil 10 mg plus Dapoxetine 30 mg Tablets, Tadalafil 20 mg plus Dapoxetine 30 mg Tablets and Tadalafil 20 mg plus Dapoxetine 60 mg Tablets in the treatment of | 2018 | Ongoing | National |
| 17. | Dr. Swati Samant | Ophthalmology | A Comparative, Randomized, Two Arm, Double Blind, Parallel group, Multicentric Clinical Study to Evaluate the Efficacy, Safety and Tolerability of Ripasudil Hydrochloride Hydrate Eye Drops 0.4% w/v Vs Timolol Maleate Eye Drops 0.5% w/v in Subjects Suffering from Ocular Hypertension / Glaucoma. | 2018 | Ongoing | National |
| 18. | Dr. Abhay Kumar Sahoo | Endocrinology | Fixed dose combination (Fdc) of repaglinide (0.5gm/1mg) + Voglibose (0.2mg/0.3mg) Phase 3 clinical Trial | 2018 | Closed | National |

| 20. | Dr. Abhay Kumar Sahoo | Endocrinology | A 12 month prospective observational study assessing the real world clinical effectiveness, safety and health economic benefits of Toujeo Initiation after oral antidiabetic drug failure in Insulin-Naïve Patient With Type- 2 Diabetes. A Phase III, Multicenter, | 2018 | Closed | International |
|-----|--|----------------------------------|--|------|---------|---------------|
| 20. | Dr. Swati Samant | Ophthalmology | Comparative, Randomized, Double blind, Two arm, Parallel group Clinical Study to evaluate Efficacy and Safety of Fixed dose combination of Alcaftadine 0.25% w/v and Ketorolac Tromethamine 0.4% w/v Eye Drops compared with Alcaftadine Ophthalmic Solution 0.25% w/v for the treatment of Subjects with Ocular Itching associated with Allergic Conjunctivitis. | 2018 | Ongoing | National |
| 21. | Dr. Sourav Kumar Mishra/Dr. Priyanka Samal | Medical Oncology/ Haematology | A Randomized, Assesor-blind, multicentre,Parallel group,two arms, clinical study to assess the efficacy, pharmacokinetics, pharmacodynamics, Immunogenecity and safety study of Rituximab (test product, Zydus) with Rituximab (Reference Product, Roche/Genetech) in patients with | 2018 | Ongoing | National |

| | | | Diffuse Large B cell Lymphoma (DLBCL). | | | |
|-----|--------------------------|--------------------|---|------|---------|---------------|
| 22. | Dr. Chandan Das | Internal Medicine | A multi-centric, open label study to evaluate safety and efficacy of fixed dose combination of Olmesartan Medoxomil, Chlorthalidone and Cilnidipine Tablet in the treatment of essential hypertension in India. | 2019 | Ongoing | National |
| 23. | Dr. Abhay Kumar Sahoo | Endocrinology | A Phase III Randomized, Double Blind, Parallel Group, Placebo Controlled, Multicentre, Multinational Study to Evaluate Efficacy and Safety of TRC150094 as an Add On to Standard of Care in Improving Cardiovascular Risk in Subjects with Diabetes, Dyslipidemia and Hypertension | 2019 | Closed | International |
| 24. | Dr.E Venkata Rao | Community Medicine | Immune lot-to-lot consistency and non-inferiority of SHAN6 TM vaccine in comparison to SHAN 5 [®] + SHANIPV TM when administered as three doses at 6-8, 10-12 and 14-16 weeks of age in healthy Indian infants concomitantly with oral rotavirus vaccine | 2019 | Closed | National |
| 25. | Dr. Abhay Kumar Sahoo | Endocrinology | Pemafibrate to Reduce cardiovascular outcomes by reducing triglycerides IN patients with diabetes (PROMINENT). | | Closed | International |

| 26. | | | A multicentric, open label, | | | |
|-----|----------------------------|------------------|--------------------------------------|------|---------|----------|
| | Dr. Abhay Kumar | | randomized, case-control study on | | | National |
| | Sahoo | Endocrinology | Safety and Efficacy of Sofinox | | Ongoing | |
| | Sanoo | | Hydrogel (Fusidic acid gel) in | 2019 | | |
| | | | Diabetic wound healing. | | | |
| 27. | | | A Randomized, Double Blind, | | | |
| | | | Double- Dummy, Multi Center, | | | |
| | | | Parallel, Phase III Study to | | | |
| | | | Evaluate the Efficacy and Safety | | | |
| | | | of Tacrolimus Lipid Tablets | | | |
| | Dr. Ivoti Donion | | (Manufactured by Intas | | | National |
| | Dr. Jyoti Ranjan Parida | Immunology | Pharmaceuticals Ltd) Compared | | Ongoing | |
| | Parida | | to Progaf (Tacrolimus Immediate | 2019 | | |
| | | | Release Capsules-Astellas Pharma | | | |
| | | | Canada, Inc) in Adult Patients | | | |
| | | | with Active Rheumatoid Arthritis | | | |
| | | | Who have resistance OR | | | |
| | | | Intolerance to DMARDs. | | | |
| 28. | | | A Prospective, Multi Centre, | | | |
| | | | Observational, Data Collection | | | |
| | | | Registry Study to Monitor The | 2019 | | |
| | | | Routine Clinical Use Of Mabtas | | | National |
| | Dr Priyanka Samal | Haematology | (Rituximab 100 Mg / 500 Mg | | Ongoing | |
| | | | Concentrate For Solution For | | | |
| | | | Infusion, Manufactured By Intas | | | |
| | | | Pharmaceuticals Ltd) In Indian | | | |
| | | | Patients. | | | |
| 29. | | | A single arm, multicentric, open- | | | |
| | Dr. Soumya Surath | | label, efficacy, and safety study of | | | |
| | Panda | Medical Oncology | Doceaqualip (Docetaxel Lipid | | Ongoing | |
| | 1 anua | | Suspension for Injection of Intas | 2019 | | National |
| | | | Pharmaceuticals Limited, India) | | | |

| | | I | | | | |
|-----|----------------------------|--------------------|-------------------------------------|------|---------|---------------|
| | | | based regimens in metastatic | | | |
| | | | gastric adenocarcinoma patients. | | | |
| 30. | | | A Phase III, Multi-center, Multi | | | |
| | | | country, Open label, randomized, | | | |
| | | | active controlled clinical trial to | | | |
| | Dr. Taras Darian | | evaluate the efficacy and safety of | | | |
| | Dr. Tapas Ranjan Behera | | Desidustat versus Darbopoetin for | 2019 | Ongoing | National |
| | Benera | | the treatment of Anemia in | | | |
| | | | patients with chronic kidney | | | |
| | | | disease (CKD) who are not on | | | |
| | | Nephrology | Dialysis. | | | |
| 31. | | | An Open label, Multi-centric, | | | |
| | | | Prospective, Clinical Trial to | 2019 | | |
| | | | Evaluate safety and efficacy of | | | |
| | | | Fixed Dose combination of | | | National |
| | Dr.Rakhi Ludam | | Montelukast 10Mg plus | | Ongoing | |
| | | | Acebrophylline SR 200Mg | | | |
| | | | Tablets in Patients having | | | |
| | | Pulmonary Medicine | Bronchial Asthma in India | | | |
| 32. | | | A Phase IV Study to Evaluate the | | | |
| 0 | | | knmunogenicity and Safety of | 2019 | | |
| | | | Purified Vi capsular polysacchari | 2017 | | National |
| | Dr.E Venkata Rao | Community Medicine | de lof Salmonella typhi, Ty2 | | Ongoing | i tutionui |
| | | Community Medicine | skain) tetanus toxoid | | ongoing | |
| | | | conjugate vaccine; Typbar-TCV@ | | | |
| | | | in Adults | | | |
| 33. | | | A Phase III, Multicenter, | | | |
| 55. | | | Randomized, Double-blind study | 2019 | | |
| | | | to assess Efficacy and Safety of | | | |
| | Dr Priyanka Samal | Haematology | Two Doses of Crizanlizumab | | Ongoing | International |
| | | | versus Placebo, With or Without | | | International |
| | | | Hydroxyurea/ hydroxycarbamide | | | |
| | | | injuloxyulcu/ nyuloxycarbannuc | | | |

| | | | Therapy, in Adolescent and Adult | 2019 | | |
|-----|----------------------------|--------------------|--------------------------------------|------|---------|----------|
| | | | Sickel Cell Diseases Patients with | | | |
| | | | Vaso-Occlusive Crises(STAND) | | | |
| 34. | | 6 | A Phase III, Multi-center, Open | | | |
| | | | label, randomized, active- | | | |
| | | | controlled study to evaluate the | | | |
| | Dr. Torge Derior | | efficacy and safety of Desidustat | | | National |
| | Dr. Tapas Ranjan Behera | Nephrology | tablet versus Epoetin alfa | 2019 | Ongoing | |
| | Benera | | injection for the treatment of | | | |
| | | | Anemia in patients with chronic | | | |
| | | | kidney disease (CKD) on Dialysis | | | |
| | | | (DREAM-D) | | | |
| 35. | | | A Phase IV Randomized, | | | |
| | | | Controlled Study to Evaluate the | | | |
| | Dr.E Venkata Rao | Community Medicine | Immunogenicity and Safety of | 2020 | Ongoing | |
| | | | Inactivated Japanese Encephalitis | | | National |
| | | | Vaccine in healthy Volunteers. | | | |
| 36. | | | A prospective, randomized, two- | | | |
| | | | arm, parallel, single-blind, active- | 2020 | | |
| | | | controlled, multicentre, non- | | | |
| | | | inferiority clinical study to | | | |
| | | | evaluate the immunogenicity and | | | |
| | | | safety of Diphtheria and Tetanus | | | National |
| | Dr.E Venkata Rao | Community Medicine | vaccine (adsorbed) for adults and | | Ongoing | |
| | | | adolescents I.P. of M/s. Cadila | | | |
| | | | Healthcare Limited compared to | | | |
| | | | Diphtheria and Tetanus vaccine | | | |
| | | | (adsorbed) for adults and | | | |
| | | | adolescents I.P. of M/s. Biological | | | |
| 27 | Du Comment Comment | | E Limited in healthy subjects. | | | |
| 37. | Dr. Soumya Surath | Medical Oncology | A Multicentre, Double-Blind, | | Ongoing | No.411 |
| | Panda | | Randomized, Parallel-Group, | | | National |

| 1 | | | Active-Controlled, Two Part, | 2020 | | |
|-----|--------------------|--------------------|------------------------------------|------|---------|---------------|
| | | | , | 2020 | | |
| | | | Phase III, Global Study to | | | |
| | | | Evaluate the Pharmacokinetics, | | | |
| | | | Efficacy and Safety of BP02 | | | |
| | | | (Trastuzumab) in Comparison | K | | |
| | | | with Herceptin-EU in Patients | | | |
| | | | with HER2-Positive Early Breast | | | |
| | | | Cancer (EBC) and HER2 Positive | | | |
| | | | Metastatic Breast Cancer (MBC). | | | |
| 38. | | | An Open label, Multi-Centre, | | | |
| | | | Randomized, Two-treatment, | | | |
| | | | Multi dose, Parallel Comparative | | | |
| | | | Bioavailability Study of | 2020 | | |
| | Dr Priyanka Samal | Haematology | Bortezomib Injection 3.5 mg/0.2 | | Ongoing | National |
| | | | ml and VELCADE 3.5 mg | | | |
| | | | powder for solution for injection | | | |
| | | | at a dose of 1.3 mg/m2 in | | | |
| | | | Multiple Myeloma patients. | | | |
| 39. | | | Phase IV Multi-center, | | | |
| | | | Prospective, Interventional, Post- | 2020 | | |
| | | | marketing Study in Hemophilia B | _0_0 | | |
| | Dr Priyanka Samal | | Patients in India receiving | | Ongoing | International |
| | Di i iiyumku Sumur | | RIXUBIS as On- demand or | | ongoing | international |
| | | | Prophylaxis Under Standard | | | |
| | | Haematology | Clinical Practice. | | | |
| 40. | | Thematology | A Phase 3, Randomized, | | | |
| -0. | | | Observer-blind, Controlled, | | | |
| | | | Multi-Center Study to Evaluate | | | |
| | Dr. Sandeep Kumar | | the Lot to Lot Consistency of | | Ongoing | National |
| | Panigrahi | | SIIPL Meningococcal ACYWX | | Ongoing | TNational |
| | | | Conjugate Vaccine (NmCV-5) | 2020 | | |
| | | Community Modicine | and to Compare its Safety and | 2020 | | |
| | | Community Medicine | and to compare its safety and | | | |

| 41. | Dr.E Venkata Rao | Community Medicine | Immunogenicity with that of Licensed Meningococcal ACWY Vaccine Menactra® in Healthy Individuals 18-85 Years of Age. An adaptive seamless Phase 1, followed by Phase 2 Randomized, Double-blind, Multicenter Study to Evaluate the Safety, Reactogenicity, Tolerability and Immunogenicity of the Whole- Virion Inactivated SARS-CoV-2 Vaccine (BBV152) in Healthy Volunteers. | 2020 Ongoing | National |
|-----|--|--------------------|--|-----------------|----------|
| 42. | Dr. Suryaprakash Sibanarayan Choudhury | Neurology | A Phase III Randomized, Multi- centric, Double-blind, Doubledummy, Parallel-group Non-inferiority Study to Evaluate Efficacy and Safety of Fixed Dose Combination of Pregabalin and Duloxetine Capsule compared to Monotherapy of Pregabalin Capsule in Patients with Moderate to Severe Neuropathic Pain | Closed | National |
| 43. | Dr Priya N Nayak | Medical Oncology | A randomized, open label, multi- center, two-treatment, two-period, two-sequence,two-way cross- over, multiple dose, steady-state Bioequivalence (BE) study ofPazopanib HCl 200mg Tablets at a dose of 800 mg (4 * 200 mg tablets) of TorrentPharmaceuticals Ltd., India with | 2020 Ongoing | National |

| | | Γ | | 1 | Г | |
|-----|---------------------|--------------------|------------------------------------|------|---------|---------------|
| | | | VOTRIENT®(Pazopanib HCl | | | |
| | | | 200mg) Tablets at adose of 800 | | | |
| | | | mg ($4 * 200$ mg tablets) of | | | |
| | | | Novartis Pharmaceuticals | | | |
| | | | Corporation, USAin subjects with | | | |
| | | | Advanced renal cell carcinoma | | | |
| | | | under fasting condition. | | | |
| 44. | | | An Event-Driven, Phase3, | | | |
| | | | Randomized, Double-blind, | | | |
| | | | Placebo-controlled, Multicenter | 2020 | | |
| | | | Study to Evaluate the Efficacy, | | | National |
| | Dr.E Venkata Rao | Community Medicine | Safety, Immunogenicity, and Lot- | | Ongoing | |
| | | | to-Lot consistency of | | | |
| | | | BBV152, a Whole- virion | | | |
| | | | Inactivated SARS-CoV-2 Vaccine | | | |
| | | | in Adults≥18Years of Age. | | | |
| 45. | | | A Multicenter, Randomized, | | | |
| | | | Double-Blind. Parallel-Group, | | | |
| | | | Study to Assess the Efficacy and | | | International |
| | Dr. Ayaskanta Singh | Gastroenterology | Safety of Oral Etrasimod as | 2020 | Closed | |
| | , | | Induction and Maintenance | | | |
| | | | Therapy for Moderately to | | | |
| | | | Severely Active Crohn's Diseases. | | | |
| 46. | | | A prospective, multicenter, | | | |
| | | | randomized, double blind, Phase | | | |
| | | | III study to compare the efficacy | | | |
| | | | and safety of Biosimilar | | | National |
| | Dr. Jyoti Ranjan | Immunology | Adalimumab injection of Enzene | 2020 | Ongoing | |
| | Parida | | Biosciences Ltd. with HUMIRA® | | | |
| | | | (adalimumab) injection in subjects | | | |
| | | | with active Ankylosing | | | |
| | | | spondylitis (AS). | | | |

| 47. | Dr. Manisha Sahu | Gynecology | A randomized, double blind, parallel group, placebo-controlled, three arm, multicenter study to evaluate the Efficacy and Safety of Estradiol Vaginal Inserts USP 10 mcg in healthy postmenopausal women with symptoms of vulvar and vaginal atrophy [Group I (Test): Estradiol Vaginal Inserts USP 10 mcg of Aurobindo Pharma Ltd, India; | 2020 | Ongoing | National |
|-----|------------------|--------------------|--|------|---------|----------|
| 48. | Dr.Rakhi Ludam | Pulmonary Medicine | Group II (Reference): Vagifem® (estradiol vaginal Inserts) 10 mcg of Novo Nordisk Inc., USA and Group III: Placebo]. A phase 3, observer-blind, randomized, controlled study to determine the safety And immunogenicity of COVOVAX [sars-cov-2 recombinant spike protein Nanoparticle Vaccine (sars-cov-2 rs) with Matrix-M1 TM adjuvant] in indian adults | 2021 | Ongoing | National |
| 49. | Dr.E Venkata Rao | Community Medicine | A monolithic phase II –III double unknown, multicenter, and unresectable, clinical trial to evaluate immunogenicity and safety of an inactivated chikungunya virus vaccine BBV 87 in healthy participants aged 12 to 65 years. | 2021 | Ongoing | National |

| 50. | | | A Multicenter, open-label, non- | 2021 | | |
|-----|------------------|--------------------|---------------------------------------|------|---------|---------------|
| | Dr. Suryaprakash | | comparative clinical trial to | | | |
| | Sibanarayan | Neurology | evaluate safety and tolerability of | | Ongoing | National |
| | Choudhury | | lacosamide injection in patients | | 0 0 | |
| | j | | with partial onset seizures. | | | |
| 51. | | | A prospective, randomized, | | | |
| | | | parallel, multicentric, Phase III | | | |
| | | | clinical trial to assess the efficacy | | | |
| | | | and safety of molnupiravir 800 | | | |
| | | | mg capsules and standard of care | | | National |
| | Dr.Rakhi Ludam | Pulmonary Medicine | (SOC) compared to standard of | | Ongoing | |
| | | | care (SOC) only in patients with | 2021 | | |
| | | | polymerase chain reaction (RT- | | | |
| | | | PCR) confirmed mild COVID-19 | | | |
| | | | infection. | | | |
| 52. | | Community Medicine | A Prospective, multicentre, Phase | 2021 | | |
| | | | II Seamlessly Followed by Phase | | Ongoing | |
| | | | III Clinical Study to Evaluate the | | | |
| | | | Immunogenicity and Safety of | | | National |
| | Dr.E Venkata Rao | | Biological E's CORBEVAX | | | |
| | | | Vaccine for Protection Against | | | |
| | | | COVID-19 Disease When | | | |
| | | | Administered to COVID-19- | | | |
| | | | Negative Adult Subjects. | | | |
| 53. | | Internal Medicine | A parallel-group, Phase III, multi- | 2021 | Ongoing | |
| | | | stage, modified double-blind, | | | |
| | | | multi-armed study to assess the | | | |
| | | | efficacy, safety, and | | | International |
| | Dr. Chandan Das | | immunogenicity of two SARS- | | | |
| | | | CoV-2 Adjuvanted Recombinant | | | |
| | | | Protein Vaccines (monovalent and | | | |
| | | | bivalent) for prevention against | | | |

| | | | COVID-19 in adults 18 years of | | | |
|-----|---------------------------------|--------------------|-------------------------------------|------|-----------|----------|
| | | | age and older | | | |
| 54. | | Pediatric | A phase 3, Observer blind, | 2021 | Ongoing | |
| 54. | | reulaulic | Randomized, Active-controlled | 2021 | Oligoling | |
| | | | · | | | |
| | | | trial evaluating the immunologic | | | NI-ti1 |
| | | | non-inferiority, safety and | | | National |
| | | | tolerability of a 15-valent | | | |
| | | | pneumococcal conjugate vaccine | | | |
| | | | in healthy infants given with | | | |
| | Dr Dillip Kumar Dash | | routine pediatric vaccinations. | | | |
| 55. | | | Phase 3, prospective, multi-center, | 2021 | Ongoing | |
| | | | open label study to investigate | | | |
| | | | safety, immunogenicity, and | | | |
| | | Haematology | hemostatic efficacy of PEGylated | | | National |
| | | Theonimionogy | factor VIII (BAX 855) in | | | |
| | | | previously untreated patients | | | |
| | | | (PUPs) < 6years with severe | | | |
| | Dr Priyanka Sam <mark>al</mark> | | haemophilia A (FVIII < 1%). | | | |
| 56. | | Community Medicine | A Phase II/III Multicentric | | | |
| | | | Randomized Single Blind Study | | | |
| | | | to compare the Immunogenicity | 2021 | Ongoing | |
| | | | and Safety of Diphtheria and | | | |
| | | | Tetanus vaccine (Adsorbed) for | | | National |
| | | | Adults and Adolescents I.P of | | | |
| | | | HBI with BE Td® Vaccine in two | | | |
| | Dr Lipilekha Pattnaik | | age groups of Healthy Subjects. | | | |
| 57. | | Ophthalmology | A Phase IV, Multicentre, Open | | Ongoing | |
| | | | Label Clinical Study to Evaluate | | | |
| | Dr Lolly Pattnaik | | The Safety and Efficacy of | 2021 | | National |
| | Di Lony Faullaik | | Intracameral Phenocaine Plus | | | |
| | | | Injection for Anaesthesia and | | | |
| | | | Mydriasis in Cataract Surgery | | | |

| 58. Dr.E Venkata Rao | Community Medicine | A Phase 2 randomized, multi-centric, Clinical Trial of Heterologus Prime- Boost Combination of SARS- CoV-2 Vaccines to evaluate the immunogenicity and safety of BBV152 (COVAXIN®) with BBV154 (Adenoviral Intranasal COVID-19 vaccine) in Healthy Volunteers. | 2021 Ongoing | National |
|-------------------------|--------------------|--|--------------|----------|
| | | O BE UNI | | |